scholarly journals Role of a gamma-aminobutryic acid (GABA) receptor mutation in the evolution and spread ofDiabrotica virgifera virgiferaresistance to cyclodiene insecticides

2013 ◽  
Vol 22 (5) ◽  
pp. 473-484 ◽  
Author(s):  
H. Wang ◽  
B. S. Coates ◽  
H. Chen ◽  
T. W. Sappington ◽  
T. Guillemaud ◽  
...  
2016 ◽  
Vol 27 (4) ◽  
pp. 449-455 ◽  
Author(s):  
Ghulam Abbas ◽  
Wajahat Mahmood ◽  
Nurul Kabir

AbstractDespite their possible causative role, targeting amyloidosis, tau phosphorylation, acetylcholine esterase, glutamate, oxidative stress and mitochondrial metabolism have not yet led to the development of drugs to cure Alzheimer’s disease (AD). Recent preclinical and clinical reports exhibit a surge in interest in the role of GABAergic neurotransmission in the pathogenesis of AD. The interaction among GABAergic signaling, amyloid-β and acetylcholine is shown to affect the homeostasis between excitation (glutamate) and inhibition (GABA) in the brain. As a consequence, over-excitation leads to neurodegeneration (excitotoxicity) and impairment in the higher level functions. Previously, the glutamate arm of this balance received the most attention. Recent literature suggests that over-excitation is primarily mediated by dysfunctional GABA signaling and can possibly be restored by rectifying anomalous metabolism observed in the GABAergic neurons during AD. Additionally, neurogenesis and synaptogenesis have also been linked with GABAergic signaling. This association may provide a basis for the needed repair mechanism. Furthermore, several preclinical interventional studies revealed that targeting various GABA receptor subtypes holds potential in overcoming the memory deficits associated with AD. In conclusion, the recent scientific literature suggests that GABAergic signaling presents itself as a promising target for anti-AD drug development.


1982 ◽  
Vol 4 (5) ◽  
pp. 413-418 ◽  
Author(s):  
C NISHIMURA ◽  
S OHKUMA ◽  
J TAMURA ◽  
K KURIYAMA

2010 ◽  
Vol 588 (1) ◽  
pp. 59-66 ◽  
Author(s):  
Alpa Khatri ◽  
David S. Weiss
Keyword(s):  

CNS Drugs ◽  
2017 ◽  
Vol 31 (10) ◽  
pp. 845-856 ◽  
Author(s):  
Janette Brohan ◽  
Basavana G. Goudra

2020 ◽  
Vol 18 (4) ◽  
pp. 307-321
Author(s):  
Bingli Cheng ◽  
Yanfei Liu ◽  
Jinfan Tian ◽  
Rui Gao ◽  
Yue Liu

Insomnia is a widespread sleep disorder in the general population, and it is a risk factor for impaired function, the development of other medical and mental disorders, and causes an increase in health care costs. In view of the health hazards of insomnia and the shortcomings of western medicine, Complementary and Alternative Medicine (CAM) should be considered in the management of insomnia. The present overview reports the potential role of herbal medicine and non-pharmacological therapies in the treatment of insomnia and summarizes the scientific evidence reported from 2008 to 2018. PubMed and Web of Science databases were searched for studies published from 2008 to 2018. 17 randomized controlled trials and 22 non-pharmacological therapies were included in this review, and the results showed that CAM had certain advantages in the treatment of insomnia. The safety of CAM for insomnia was acceptable. Meanwhile, based on pre-clinical trial, the possible mechanisms of CAM for insomnia were modulation of circadian rhythm, GABA receptor activation, antagonisms of 5-HT receptors, inhibition of glutamate-mediated pathways, and attenuation of inflammation. CAM for insomnia has made some progress, but high quality evidence-based medical evidence is still needed to provide guidance for clinical application.


Author(s):  
Xianshu Bai ◽  
Frank Kirchhoff ◽  
Anja Scheller

AbstractGABA is the main inhibitory neurotransmitter in the CNS acting at two distinct types of receptor: ligand-gated ionotropic GABAA receptors and G protein-coupled metabotropic GABAB receptors, thus mediating fast and slow inhibition of excitability at central synapses. GABAergic signal transmission has been intensively studied in neurons in contrast to oligodendrocytes and their precursors (OPCs), although the latter express both types of GABA receptor. Recent studies focusing on interneuron myelination and interneuron-OPC synapses have shed light on the importance of GABA signaling in the oligodendrocyte lineage. In this review, we start with a short summary on GABA itself and neuronal GABAergic signaling. Then, we elaborate on the physiological role of GABA receptors within the oligodendrocyte lineage and conclude with a description of these receptors as putative targets in treatments of CNS diseases.


Sign in / Sign up

Export Citation Format

Share Document